DoW Duchenne Muscular Dystrophy, Idea Development Award

The Duchenne Muscular Dystrophy Research Program Idea Development Award is offered by the Defense Health Agency through the Congressionally Directed Medical Research Programs, a federal initiative established to fund high-impact biomedical research aligned with military and public health priorities. The program was initiated by Congress in 2011 and has received substantial appropriations to support innovative research into Duchenne muscular dystrophy, a severe genetic disorder that affects muscle function across the lifespan. The funding opportunity is administered as part of a broader effort to advance therapies, improve patient outcomes, and contribute to scientific discovery relevant to both civilian and military populations. The purpose of this award is to support early-stage, high-risk, high-reward research that has the potential to generate impactful findings and open new avenues of investigation. Applicants are expected to propose research grounded in a strong scientific rationale with a clearly defined, testable hypothesis. The program emphasizes innovation and encourages projects that could accelerate progress toward effective treatments for Duchenne muscular dystrophy, particularly those that address therapeutic development across all stages of life, including pediatric and nonambulatory populations. Funding under this opportunity is structured as a grant mechanism with a maximum total cost of 500000 dollars per award and a performance period of up to two years. The program anticipates awarding approximately five grants with a total allocation of approximately 2.5 million dollars. Funds may be used for research-related expenses, including collaborative travel and dissemination of findings, but may not be used to support clinical trials. Applicants must include preliminary data demonstrating feasibility, and all proposed work must adhere to rigorous research design and reporting standards. Eligibility for this opportunity is broad and inclusive, allowing applications from both domestic and international organizations across public, private, nonprofit, and for-profit sectors. Principal Investigators must be independent researchers affiliated with an eligible organization and must select one of three career categories: Established Investigator, New Investigator Early Stage, or New Investigator Transitioning. Each category has specific criteria, including experience level and research focus, and applicants are evaluated within their chosen category. Cost sharing is not required, and awards are made to organizations rather than individuals. The application process consists of two required steps: submission of a pre-application in the form of a Letter of Intent through the eBRAP system, followed by a full application submitted via Grants.gov or eBRAP depending on the applicant type. The Letter of Intent is used for planning purposes and does not influence review outcomes. Full applications require multiple components, including a detailed project narrative, technical and lay abstracts, statement of work, impact statement, and supporting documentation. Applications are evaluated through a two-tier review process involving peer review and programmatic review, with criteria focusing on impact, scientific merit, feasibility, personnel qualifications, and potential research outcomes. Key deadlines for this funding opportunity include a pre-application submission deadline of September 4, 2026, and a full application deadline of September 18, 2026. Peer review is expected to occur in December 2026, followed by programmatic review in February 2027. Awards are anticipated to be issued no later than September 30, 2027. Applicants can seek technical assistance through the eBRAP Help Desk or Grants.gov Support Center, and must ensure that all required registrations, including SAM.gov, are active prior to submission.

Emphasize high impact and strong scientific rationale supported by preliminary data; ensure feasibility and alignment with DMD therapeutic development priorities; clearly articulate near term impact and military relevance